In what age groups is Rozebalamin (methylcobalamin) suitable for patients?

Rozebalamin(methylcobalamin) is a drug used to treat amyotrophic lateral sclerosis (ALS). Its indications are mainly concentrated in adult patients. Although its mechanism of action has been validated in adult patients, its suitability varies among patients of different age groups, particularly for use in children and the elderly.

1. Adult patients: Rozebalamin is mainly suitable for adult patients, especially those diagnosed with amyotrophic lateral sclerosis (ALS). The drug helps patients maintain functional independence for longer by slowing the progression of the disease. Adult patients, especially those with early symptoms of ALS, are its main treatment targets. According to the drug's instructions for use, the recommended dose for adult patients is 50 mg per day, usually administered by intramuscular injection twice a week.

2. Pediatric patients: Currently, the use of Rozebalamin in pediatric patients has not been fully clinically validated. Therefore, this drug is not yet recommended for use in minors. Because the physiological characteristics of children are different from those of adults, doctors generally do not prescribe Rozebalamin for the treatment of children without relevant research support. For pediatric ALS patients, you may need to consider other treatment options and choose the most appropriate treatment plan according to your doctor's guidance.

3. Elderly patients: For elderly patients, Rozebalamin should be used with caution. Although the drug is effective in the general adult population, older adults may respond differently to the drug due to changes in physiology. When using Rozebalamin in elderly patients, doctors will adjust the dosage or frequency of use based on the patient's health status, other chronic diseases, and complications. At the same time, elderly patients may be more susceptible to side effects of the drug, so special attention and close observation are required during use.

4. Use in special populations: RozebalaminUse in special populations, including pregnant or lactating women, has not been adequately tested in clinical trials. When using this drug in these populations, the potential risks versus benefits must be fully evaluated, and doctors weigh various factors to ensure patient safety. If the patient falls into these special groups, special caution should be taken when using this drug and the strict instructions of the physician should be followed.

xa0

References:

[1]https://pins.japic.or.jp/pdf/newPINS/00071540.pdf

[2]https://www.eisai.com/news/2024/news202487.html